169 related articles for article (PubMed ID: 24685823)
1. Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine.
Mesholam-Gately RI; Gibson LE; Seidman LJ; Green AI
Schizophr Res; 2014 May; 155(1-3):45-51. PubMed ID: 24685823
[TBL] [Abstract][Full Text] [Related]
2. Substance abuse and schizophrenia: pharmacotherapeutic intervention.
Green AI; Noordsy DL; Brunette MF; O'Keefe C
J Subst Abuse Treat; 2008 Jan; 34(1):61-71. PubMed ID: 17574793
[TBL] [Abstract][Full Text] [Related]
3. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.
Green AI
J Clin Psychiatry; 2006; 67 Suppl 7():31-5; quiz 36-7. PubMed ID: 16961422
[TBL] [Abstract][Full Text] [Related]
4. The effects of clozapine on aggression and substance abuse in schizophrenic patients.
Volavka J
J Clin Psychiatry; 1999; 60 Suppl 12():43-6. PubMed ID: 10372611
[TBL] [Abstract][Full Text] [Related]
5. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?
Green AI; Zimmet SV; Strous RD; Schildkraut JJ
Harv Rev Psychiatry; 1999; 6(6):287-96. PubMed ID: 10370435
[TBL] [Abstract][Full Text] [Related]
6. Sexual side effects of novel antipsychotic medications.
Wirshing DA; Pierre JM; Marder SR; Saunders CS; Wirshing WC
Schizophr Res; 2002 Jul; 56(1-2):25-30. PubMed ID: 12084416
[TBL] [Abstract][Full Text] [Related]
7. Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review.
Arranz B; Garriga M; García-Rizo C; San L
Eur Neuropsychopharmacol; 2018 Feb; 28(2):227-242. PubMed ID: 29273271
[TBL] [Abstract][Full Text] [Related]
8. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
Potvin S; Stip E; Roy JY
Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for schizophrenia and co-occurring substance use disorders.
Green AI
Neurotox Res; 2007 Jan; 11(1):33-40. PubMed ID: 17449446
[TBL] [Abstract][Full Text] [Related]
10. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone.
Green AI; Burgess ES; Dawson R; Zimmet SV; Strous RD
Schizophr Res; 2003 Mar; 60(1):81-5. PubMed ID: 12505141
[TBL] [Abstract][Full Text] [Related]
11. Substance abuse in schizophrenia: a review.
Buckley PF
J Clin Psychiatry; 1998; 59 Suppl 3():26-30. PubMed ID: 9541335
[TBL] [Abstract][Full Text] [Related]
12. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW
Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
[TBL] [Abstract][Full Text] [Related]
14. Clozapine for substance-abusing schizophrenic patients.
Tsuang JW; Eckman TE; Shaner A; Marder SR
Am J Psychiatry; 1999 Jul; 156(7):1119-20. PubMed ID: 10401473
[No Abstract] [Full Text] [Related]
15. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
Krakowski MI; Czobor P; Nolan KA
J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
[TBL] [Abstract][Full Text] [Related]
16. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
17. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis.
Potvin S; Joyal CC; Pelletier J; Stip E
Schizophr Res; 2008 Mar; 100(1-3):242-51. PubMed ID: 17614260
[TBL] [Abstract][Full Text] [Related]
18. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study].
Mazza M; Tozzini C; Giosué P; De Risio A; Palmucci M; Roncone R; Casacchia M
Clin Ter; 2003; 154(2):79-83. PubMed ID: 12856365
[TBL] [Abstract][Full Text] [Related]
19. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
[TBL] [Abstract][Full Text] [Related]
20. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.
Brunette MF; Drake RE; Xie H; McHugo GJ; Green AI
Schizophr Bull; 2006 Oct; 32(4):637-43. PubMed ID: 16782758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
